Viridian Therapeutics

VRDN

Market cap $1.5B

The Phase 3 TEPEZZA OBI trial met its primary endpoint, showing a statistically significant 77% proptosis (bulging eyes) response rate among participants during the 24-week placebo-controlled period.

Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company's REVEAL-1 trial in active thyroid eye disease (TED). The study, which tested the subcutaneous formulation of elegrobart, met its primary endpoint, signaling that the drug could gain approval.

The REVEAL-1 trial met its primary endpoint, showing a statistically significant treatment effect with elegrobart achieving a proptosis (abnormal protruding eyes) responder rate of 54% and 63% for the Q4W (once in four weeks) and every eight weeks (Q8W) dosing regimens, respectively, compared to 18% for placebo at week 24.

Viridian Therapeutics stock crashed Monday on "positive, but lackluster" final-phase results for its thyroid eye disease treatment.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease (TED). Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor (.

Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing. Meanwhile, the quarter-end Viridian position value fell by $49.79 million, reflecting both trading and price movements.

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $0.81 per share a year ago.